Metabolic profiling of lysophosphatidylcholines in chlorpromazine hydrochloride- and N-acetyl-p-amino-phenoltriptolide-induced liver injured rats based on ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry. (10th June 2022)

• Record Type: Journal Article
• Authors: Hu, Cong; Li, Hong-Wei; Ke, Jia-Qun; Yu, Xue-Chun; Zhao, Mei-Yu; Shi, Xin-Yue; Wu, Lin-Jing; Tang, Xi-Lan; Xiong, Yin-Hua
• Is Part Of: Human & experimental toxicology. Volume 41(2022)
• Publication Date: 2022-06-10
• Subjects: Lysophosphatidylcholine -- liver injury -- metabolic profiling -- chlorpromazine hydrochloride -- N-acetyl-p-amino-phenoltriptolide -- ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry; Toxicology -- Periodicals; 615.9
• DOI: 10.1177/09603271221108320
• Languages: English
• ISSNs: 0960-3271

Abstract

Chlorpromazine hydrochloride (CH) and N -acetyl- p -amino-phenoltriptolide (APAP) are typical acentral dopamine receptor antagonists and antipyretic analgesics in clinical applications, respectively. However, it has been reported that these 2 drugs could cause liver damage. Lysophosphatidylcholines (LPCs) have multiple physiological functions and are metabolized primarily in the liver, where it undergoes significant changes when the liver is damaged. In the study, 15 LPCs in the rat serum with CH- and APAP-induced liver injury were quantified based on ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry, and multivariate statistical analyses including principal component analysis (PCA) and orthogonal partial least squares discriminate analysis (OPLS-DA) were combined to understand CH- and APAP-induced liver injury from the perspective of LPC metabolic profiling. The quantitative results showed that there were significant changes in 10 LPCs and 5 LPCs after CH- and APAP-administration, separately. The results of PCA and OPLS-DA indicated that CH- and APAP-induced liver injury could be well distinguished by the LPC metabolic profiling, and 7 LPCs and 1 LPC biomarkers that could characterize CH- and APAP-induced liver damage in turn had been screened. This study will not only provide a new perspective for the clinical diagnosis of CH- and APAP-induced liver injury, but also offer a reference for further study of their hepatotoxicity mechanisms.